PIONEER EDGE NEWS SERVICE/ Dehradun
The Indian Institute of Technology (IIT) Roorkee has claimed to have developed a next-generation antibody discovery platform with the potential to transform diagnostics and therapeutics for diseases of national and global importance.
The breakthrough research led by scientists at IIT Roorkee involves the development of an ultra-large, high-diversity single-domain antibody (nanobody) library. The platform enables rapid identification of highly stable and high-affinity antibodies against a wide range of targets, including infectious diseases, cancer, autoimmune disorders and emerging pathogens. By significantly reducing discovery timelines, the innovation addresses a critical gap in healthcare response, particularly during public health emergencies.
“By developing a universal, high-diversity antibody discovery system within India, we are strengthening national capabilities for faster disease response and accelerating the development of affordable diagnostics and therapeutics for populations that need them the most,’’ said Rajesh Kumar of the department of Biosciences and Bioengineering of IIT Roorkee. He said that the initiative also complements national efforts to promote translational research, enhance pandemic preparedness, and build long-term healthcare resilience.
The IIT Roorkee director KK Pant said, “This development demonstrates how fundamental research, combined with translational intent and industry collaboration can address pressing societal challenges. IIT Roorkee remains committed to advancing solutions that strengthen India’s position as a global hub for responsible and impactful healthcare innovation.”
In order to support technology transfer, scale-up and validation of antibody-based solutions, the IIT Roorkee has inked a Memorandum of Understanding (MoU) with IMGENEX India Private Limited. The MoU will promote collaborative research, co-development of advanced biologics and help in capacity building in areas such as antibody engineering, diagnostics, therapeutics and bioprocess development.
